Zevra Gains Support of Adcomm, Clears Hurdle for Potential Rare Disease Approval

An FDA advisory committee agreed on Friday that Zevra Therapeutics had provided sufficient efficacy data supporting the approval of arimoclomol for Niemann-Pick disease type C.